Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-12T16:01:09.728Z Has data issue: false hasContentIssue false
  • English
  • Français

Growth Hormone Rebound After Cessation of SMS 201-995 Treatment in Acromegaly

Published online by Cambridge University Press:  18 September 2015

L. Charest ,
R. Comtois ,
H. Beauregard  and
O. Serri
L. Charest
Affiliation:
Department of Medicine, Endocrinology Division, Notre-Dame Hospital, University of Montreal
R. Comtois*
Affiliation:
Department of Medicine, Endocrinology Division, Notre-Dame Hospital, University of Montreal
H. Beauregard
Affiliation:
Department of Medicine, Endocrinology Division, Notre-Dame Hospital, University of Montreal
O. Serri
Affiliation:
Department of Medicine, Endocrinology Division, Notre-Dame Hospital, University of Montreal
*
Endocrinology, Notre-Dame Hospital, 1560 Sherbrooke East, Montréal, Québec Canada H2L 4K8
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We studied a 42-year-old woman who had persistent active acromegaly despite conventional therapies. She was treated for 6 months with SMS 201-995. Her mean plasma growth hormone GH values decreased during treatment from 9.1 ± 1.2 to 6.6 ± 1.2 µg/L. One month after the withdrawal of SMS 201-995, the plasma GH level increased to 24.4 µg/L (P < 0.001). This elevation was clinically silent and transitory, as GH levels decreased 8 months later to 6.9 ± 1.3 µg/L. Furthermore, at the beginning of therapy, her intractable headache was completely relieved; however, it progressively resumed under therapy. In conclusion, cessation of SMS 201-995 may be followed in some acromegalic patients by a rebound of plasma GH levels. This rebound suggests that SMS 201-995 decreases GH levels by an inhibition of its release from the pituitary. Furthermore, SMS 201-995 may relieve intractable headache in some acromegalic patients, but tolerance to the analgesic effect may develop.

Résumé:

RÉSUMÉ:

Nous avons évalué une malade de 42 ans qui demeurait avec une acromégalie active en dépit des traitements conventionnels. Elle fût donc traitée pendant 6 mois avec du SMS 201-995. Ses niveaux moyens d'hormone de croissance (GH) ont diminué en cours de traitement de 9.1 ± 1.2 à 6.6 ± 1.2 µg/L. Un mois après l'arrêt du SMS 201-995, les valeurs moyennes plasmatiques du GH avaient augmenté à 24.4 µg/L (P < 0.001). Cette hausse fût cliniquement silencieuse et transitoire; ainsi, les niveaux de GH diminuaient à 6.9 ± 1.3 µg/L, 8 mois plus tard. De plus, les céphalées rebelles de la malade sont complètement disparues au début de la thérapie. Cependant, au cours du traitement, les céphalées sont progressivement réapparues. En conclusion, l'arrêt de SMS 201-995 peut être suivi chez certains acromégales par un rebond des niveaux plasmatiques de GH. Ce rebond suggère que le SMS 201-995 diminue les niveaux de GH par une inhibition de sa relâche hypophysaire. De plus, le SMS 201-995 peut soulager les céphalées rebelles de certains acromégales; toutefois, il peut se développer une certaine tolérance à cet effet analgésique.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 16 , Issue 4 , November 1989 , pp. 442 - 445
Copyright
Copyright © Canadian Neurological Sciences Federation 1989

References

REFERENCES

1. Ch–ng, LJC, Sandler, LM, ME, Kraenzlin, et al. Long-term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 1985; 290: 284–285.CrossRefGoogle ScholarPubMed
2. Lambert, SWJ, Uitterlinden, P, Verschoor, L, et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1985; 313: 1576–1580.Google Scholar
3. Bloom, SR Acromegaly. Am J Med 1987; 82: 88–91.CrossRefGoogle ScholarPubMed
4. Lamberts, SWJ, Oosterom, R, Neufeld, M, et al. The somatostatin analogue SMS 201–995 induces long acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60: 1161–1165.Google Scholar
5. Hardy, T Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler, PO, Ross, GT, eds. Diagnosis and treatment of pituitary tumors. Elsevier, New York 1973; 179–185.Google Scholar
6. Lamberts, SWJ, Verleun, T, Hofland, L, et al. A comparison between the effects of SMS 201–995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin Endocrinol 1987; 27: 11–23.CrossRefGoogle Scholar
7. Besser, GM, Mortimer, CH, Carr, D, et al. Growth hormone release inhibiting hormone in acromegaly. Br Med J 1974; 1: 352–355.Google Scholar
8. Besser, GM, Mortimer, CH, Me Neilly, AS, et al. Long-term infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones. Br Med J 1974; 4: 622–627.Google Scholar
9. Pieters, GFFM, Romeijm, JE, Smals, AGH, et al. Somatostatin sensitivity and growth hormone response to releasing hormones and bromocriptine in acromegaly. J Clin Endocrinol Metab 1982; 54: 942.Google Scholar
10. Buck, M, Kvols, LK, O Dorisio, TM. Rebound hypergastrinemia after cessation of a somatostatin analogue (SMS 201–995) in malignant gastrinoma. Am J Med 1987; 82: 92–95.CrossRefGoogle ScholarPubMed
11. Prysor-Jones, RA, Kennedy, SJ, O’Sullivan, JP, et al. Effect of bromocriptine, somatostatin and oestradiol-17 on hormone secretion and ultrastructure of human pituitary tumours in vitro. Acta Endocrinol 1981; 98: 14–23.Google Scholar
12. George, SR, Kovacs, K, Asa, SL, et al. Effect of SMS 201–995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma. Clin Endocrinol 1987; 26: 395–405.CrossRefGoogle ScholarPubMed
13. Sandler, LM, Burrin, JM, Williams, G, et al. Effective long term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201–995). Clin Endocrinol 1987; 26: 85–95.Google Scholar
14. Clemmons, DR, Van Wyk, JJ, EC, Ridgway, et al. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 1979; 301: 1138–1142.CrossRefGoogle ScholarPubMed
15. Williams, G, Ball, J, Bloom, SR, et al. Improvement in headache associated with prolactinoma during treatment with a somatostatin analogue: an “n of 1” study. N Engl J Med 1986; 315: 1166–1167.Google ScholarPubMed
16. Williams, G, Ball, JA, Lawson, RA, et al. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumors. Br Med J 1987; 295: 247–248.CrossRefGoogle Scholar
17. Ramirez, LF, Levin, AB. Pain relief after hypophysectomy. Neurosurgery 1984; 14: 499–504.Google Scholar
18. Terenius, L. Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors. Eur J Pharmacol 1976; 38: 211–213.Google Scholar
19. Kvols, LK, Buck, M, Moertel, CG, et al. Treatment of metastatic islet carcinoma with a somatostatin analogue (SMS 201–995). Ann Intern Med 1987; 107: 162–168.Google Scholar
20. Kvols, LK, Moertel, CG, O’Connell, MJ, et al. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue (SMS 201–995). N Engl J Med 1986; 315: 663–666.Google Scholar
21. Reisine, TD, Takahashi, JS. Somatostatin pretreatment desensitizes somatostatin receptors linked to adenylate cyclase and facilitates the stimulation of cyclic adenosine 3’: 5’–monophosphate accumulation in anterior pituitary tumour cells. J Neurosci 1984; 4: 812–819.CrossRefGoogle Scholar